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To the Editor: Partial artemisinin-resistant Plasmodium 
falciparum malaria, characterized by delayed parasite clear-
ance after treatment with artesunate or artemisinin-based 
combination therapy, was first detected in western Cambodia 
and has now spread to or emerged de novo in 5 countries of 
the Greater Mekong Subregion (GMS) (1). However, most 
reported cases of malaria have been in Africa, and detecting 
artemisinin and multidrug resistance in Africa will have con-
sequences for policy and containment plans (2). 
Thus, vigilant monitoring is pivotal, and it is therefore 
with great interest that we read the case report on a patient 
in Vietnam with severe P. falciparum malaria, acquired in 
Angola in 2013, that was not responsive to artesunate or 
several other antimalarial combinations (3). We believe 
that there are several issues that challenge the conclusion 
that artemisinin resistance has reached Angola: 1) the phe-
notypic and genotypic characteristics of the infecting strain 
in this patient were very different from artemisinin-resis-
tant strains in the GMS; 2) pharmacokinetic issues cannot 
be ruled out; and 3) perhaps of most relevance, the study 
documents severely delayed clearance of multiple strains in 
this polyclonal P. falciparum infection, suggesting splenic 
hypofunction as an important contributor.
The parasite clearance half-life calculated with the 
World Health Organization (WHO) online slope analyzer 
from the log linear segment of the clearance curve after 
start of artesunate therapy was 102.5 hours, which is ≈10 
times longer than observed in the most artemisinin-resistant 
parasites in Cambodia. Postpublication genotyping of the 
infecting strain provided by the authors to WHO showed a 
wild-type Kelch (K13) gene, which is a recently discovered 
molecular marker for artemisinin resistance strongly cor-
related to the resistant phenotype in the GMS (1).
No pharmacokinetic assessment was made, and sub-
therapeutic artesunate and dihydroartemisinin (as well as 
clindamycin, piperaquine, quinine, and doxycycline) blood 
concentrations cannot be excluded. The intravenous arte-
sunate regimen used differed from the WHO guideline of 
2.4 mg/kg on admission, after 12 h, then daily. Pharmaco-
kinetic modeling of the split doses used in the described 
case indicate that this dosing schedule results in <20% 
artesunate and dihydroartemisinin blood concentrations. In 
addition, quality issues in the artesunate batch might have 
played a major role. Batch no. 511002 used for this patient 
(not 511004 as mentioned in the article) was manufactured 
by Pharbaco (Hanoi, Vietnam) in April 2011 and had a 
shelf-life of 3 years; it was quality controlled and passed 
the quantitative testing by high pressure liquid chromatog-
raphy in January 2014 (National Institute of Drug Qual-
ity Control, Vietnam). However, according to information 
shared with WHO, a test for clarity after reconstitution was 
not performed, whereas other samples from the same batch 
had failed this specific test, which led the Drug Administra-
tion of Vietnam to withdraw this batch from the market. 
The patient was subsequently treated with nasogastric-
administered dihydroartemisinin/piperaquine and quinine 
plus doxycycline. Reduced intestinal absorption in this se-
verely ill patient, related to reduced splanchnic blood flow, 
could have resulted in reduced bioavailability (4).
Host factors can affect parasite clearance. In this case, 
the parasitological response to artesunate and clindamycin, 
dihydroartemisinin/piperaquine, quinine, and doxycycline 
were all unusually slow. Functional asplenia results in very 
slow parasite clearance after artesunate treatment, resem-
bling the clearance characteristics in the described case (5). 
This interpretation is supported by finding genotypes rep-
resenting >2 clones of parasites persisting >1 week after 
treatment with multiple antimalarial drugs. It seems very 
unlikely that this patient harbored multiple highly artemis-
inin-resistant parasite strains. Dead circulating intraeryth-
rocytic parasites in patients who have hyposplenia can be 
recognized morphologically, but the article does not pro-
vide details on this.
Circulation of multidrug resistant malarial strains in 
sub-Saharan Africa can have disastrous consequences, and 
it is critical to detect its arrival at an early stage. The case 
report by Van Hong et al. implies the unlikely event of in-
dependent emergence of multidrug resistant strains in a 
traveler from Vietnam in Angola, without evidence of local 
declining artemisinin-based combination therapy efficacy. 
WHO and partners are investigating the phenotype and 
genotype of parasite strains from the same geographic area 
in Angola to address the concerns raised above. We believe 
that this single case report is insufficient to raise the alarm.
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In Response: We agree with Ringwald and Dondorp (1)
that our report of a Vietnamese worker returning from An-
gola with severe Plasmodium falciparum malaria not respon-
sive to artemisinins (2) is unlikely to indicate that artemisinin 
resistance has reached Angola. Nevertheless, this case, for its 
unusual clinical manifestation and response to treatment, had 
raised alarm in Vietnam, where the number of imported ma-
laria cases and deaths among Vietnamese workers returning 
from Africa has recently increased (3,4). After our report was 
published in July 2014, we collected additional information 
that may be useful in putting such a case in perspective. 
The results of an external quality control study by Sig-
ma-Tau Pharmaceuticals on 10 vials of the same batch (no. 
511002) of intravenous artesunate as administered to our 
case-patient (report available on request) confirmed accept-
able drug concentration and showed that the opalescence ob-
served after reconstitution was caused by precipitation of an 
impurity (representing 0.12% of the preparation) identified 
as an active metabolite of artesunate. Therefore, the treat-
ment administered to the patient was of acceptable quality. 
The blood concentrations of artesunate and dihydroartemis-
inin may have been 20% lower than ideal (as predicted by a 
pharmacokinetic model), but this finding cannot explain why 
the parasite density remained >200,000/μL for several days.
Ringwald and Dondorp also mention functional asple-
nia as a possible cause of delayed parasite clearance. We ar-
gue that this would have resulted in a much longer (weeks/
months) parasite clearance (5) than the observed sharp de-
crease after quinine and tetracycline administration. More-
over, we did not observe any accumulation of circulating 
dead parasites (Howell-Jolly bodies), which is against the hy-
pothesis of functional asplenia. Furthermore, sharp decline of 
parasite density immediately after quinine and doxycycline 
administration by nasogastric tube is not consistent with the 
proposed hypothesis of reduced intestinal absorption.
In hindsight and after consideration of additional in-
formation, we agree that it is unlikely this patient harbored 
several resistant parasite clones. However, the reasons for 
the lack of response to arteminins in this patient remain 
unknown and are under continued investigation.
The discussion triggered by the publication of our 
case report raises the question of what should be report-
ed to the attention of the scientific community and pub-
lic health authorities. Besides being an obligation for 
clinical physicians, reporting unusual treatment failures 
such as our case is also an essential component of anti-
malarial resistance surveillance. As mentioned by Ring-
wald and Dondorp, “vigilant monitoring is pivotal” for 
the detection of possible foci of resistance. For early de-
tection of artemisinin resistance, we would rather have a 
more sensitive than specific system, because the latter 
would probably miss the first emerging cases of resistance. 
Reporting cases similar to the one we published should 
be encouraged.
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